Tag: nucleic acid based gene therapy market analysis

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Nucleic Acid Based Gene Therapy Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The nucleic acid based gene therapy market has demonstrated significant growth in recent years. This market is projected to expand from $0.88 billion in 2025 to $0.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. Historically, this expansion has been driven by several factors, including advancements in molecular biology research, a deeper understanding of genetic disease mechanisms, the expansion of clinical trials for gene therapies, rising investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.

The nucleic acid based gene therapy market is anticipated to undergo substantial expansion in the forthcoming years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. This growth over the projected period can be attributed to several factors, including the increasing integration of CRISPR-based treatments, a growing demand for therapies addressing rare diseases, the expansion of facilities for gene therapy manufacturing, an intensifying focus on personalized oncology treatments, and an uptick in public and private funding directed towards genetic medicine. Noteworthy trends for the forecast period encompass a rising adoption of RNA-based therapeutics, increased utilization of both viral and non-viral gene delivery systems, a stronger emphasis on targeted gene editing technologies, the broadening availability of personalized genetic therapies, and an enhanced focus on precision medicine applications.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=82028704&type=smp&name=Nucleic%20Acid%20Based%20Gene%20Therapy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Nucleic Acid Based Gene Therapy Market Demand Drivers: What’s Powering Industry Growth?

The future expansion of the nucleic acid based gene therapy market is anticipated to be driven by increasing financial backing from governments and private enterprises. This financial backing encompasses monetary investments, grants, or subsidies originating from public or private entities, aimed at advancing the research, development, and market availability of these treatments. The surge in financial aid stems from a heightened global focus on finding remedies for rare and genetic ailments that currently have no effective cures. Government funding specifically accelerates advancements in nucleic-acid–based gene therapy by providing critical resources for research, clinical trials, and infrastructure, which directly fosters innovation and the development of practical treatments. For example, in July 2023, the U.S. National Institutes of Health, a U.S.-based federal health research agency, allocated over $140 million to expedite genome editing methods, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders. This represents a substantial rise from the $92 million in annual funding provided in 2022. Consequently, the growing financial support from governments and companies is propelling the growth of the nucleic acid based gene therapy market.

Nucleic Acid Based Gene Therapy Market Segment Breakdown: Which Categories Lead On Revenue?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Nucleic Acid Based Gene Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?

Major companies operating in the nucleic acid-based gene therapy market are focusing on personalized, autologous stem-cell therapies, such as genetically modified hematopoietic stem-cell infusions, to treat rare inherited diseases. Autologous therapies refer to treatments in which a patient’s own stem cells are removed, genetically corrected and re-infused to restore the missing biochemical function. For instance, in March 2024, Orchard Therapeutics, a US-based company that offers pharmaceuticals announced Lenmeldy (atidarsagene autotemcel) approved by the U.S. Food and Drug Administration for children with metachromatic leukodystrophy (MLD). Lenmeldy uses the patient’s own hematopoietic stem cells that have been genetically modified to express a functional ARSA gene, enabling enzyme restoration in the nervous system. This regulatory success underscores how companies can commercialize complex, autologous gene therapies despite high manufacturing costs.

Nucleic Acid Based Gene Therapy Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

View The Full Nucleic Acid Based Gene Therapy Market Report:

https://thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

Nucleic Acid Based Gene Therapy Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Nucleic Acid Based Gene Therapy Market During The Forecast Period?

The nucleic acid based gene therapy market size has seen rapid expansion in recent years. It is projected to increase from $0.88 billion in 2025 to $0.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. This historical growth can be ascribed to advancements in molecular biology research, a deeper understanding of genetic disease mechanisms, the expansion of clinical trials for gene therapies, rising investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.

The nucleic acid based gene therapy market size is anticipated to experience substantial growth in the coming years. It is projected to reach $1.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period is driven by factors such as the increasing adoption of CRISPR-based treatments, a rising demand for therapies for rare diseases, the growth of gene therapy manufacturing facilities, a heightened focus on personalized oncology treatments, and increasing public and private funding for genetic medicine. Significant trends expected during this period include the growing uptake of RNA-based therapeutics, an increased utilization of viral and non-viral gene delivery systems, a stronger emphasis on targeted gene editing technologies, the expansion of personalized genetic therapies, and an enhanced focus on precision medicine applications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Market Drivers Are Helping Shape The Nucleic Acid Based Gene Therapy Market Expansion?

The escalating financial backing from governments and private enterprises is poised to fuel the expansion of the nucleic acid based gene therapy market in the foreseeable future. This financial assistance refers to monetary investments, grants, or subsidies originating from public or private institutions, designed to advance the research, development, and commercialization of these therapies. The surge in financial support is attributed to an increasing worldwide emphasis on developing treatments for rare and genetic diseases that currently lack effective remedies. Government funding specifically for nucleic-acid–based gene therapy accelerates progress by supplying crucial resources for research, clinical trials, and infrastructure, thereby directly driving innovation and the translation of discoveries into effective treatments. For example, in July 2023, the U.S. National Institutes of Health, a U.S.-based federal health research agency, awarded over $140 million to expedite genome editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, which marks a significant increase compared to the previous annual funding of $92 million in 2022. Therefore, the heightened financial support from governments and companies is a key driver for the growth of the nucleic acid based gene therapy market.

What Are The Major Segment Categories Within The Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

What Trends Are Influencing The Nucleic Acid Based Gene Therapy Market?

Leading companies operating in the nucleic acid-based gene therapy market are primarily focused on personalized, autologous stem-cell treatments, such as genetically modified hematopoietic stem-cell infusions, for the management of rare inherited diseases. Autologous therapies involve the removal of a patient’s own stem cells, which are then genetically corrected and re-infused to restore the missing biochemical function. For instance, in March 2024, Orchard Therapeutics, a US-based company offering pharmaceuticals, announced that Lenmeldy (atidarsagene autotemcel) had been approved by the U.S. Food and Drug Administration for use in children with metachromatic leukodystrophy (MLD). Lenmeldy utilizes the patient’s own hematopoietic stem cells, which are genetically modified to express a functional ARSA gene, thereby enabling enzyme restoration in the nervous system. This regulatory success highlights the capability of companies to commercialize intricate, autologous gene therapies despite facing high manufacturing costs.

Which Companies Form The Competitive Landscape Of The Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Access The Complete Nucleic Acid Based Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Which Region Is The Dominant Market In The Nucleic Acid Based Gene Therapy Market?

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Nucleic Acid Based Gene Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Nucleic Acid Based Gene Therapy Market During The Forecast Period?

The nucleic acid based gene therapy market size has seen rapid expansion in recent years. It is projected to increase from $0.88 billion in 2025 to $0.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. This historical growth can be ascribed to advancements in molecular biology research, a deeper understanding of genetic disease mechanisms, the expansion of clinical trials for gene therapies, rising investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.

The nucleic acid based gene therapy market size is anticipated to experience substantial growth in the coming years. It is projected to reach $1.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period is driven by factors such as the increasing adoption of CRISPR-based treatments, a rising demand for therapies for rare diseases, the growth of gene therapy manufacturing facilities, a heightened focus on personalized oncology treatments, and increasing public and private funding for genetic medicine. Significant trends expected during this period include the growing uptake of RNA-based therapeutics, an increased utilization of viral and non-viral gene delivery systems, a stronger emphasis on targeted gene editing technologies, the expansion of personalized genetic therapies, and an enhanced focus on precision medicine applications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Market Drivers Are Helping Shape The Nucleic Acid Based Gene Therapy Market Expansion?

The escalating financial backing from governments and private enterprises is poised to fuel the expansion of the nucleic acid based gene therapy market in the foreseeable future. This financial assistance refers to monetary investments, grants, or subsidies originating from public or private institutions, designed to advance the research, development, and commercialization of these therapies. The surge in financial support is attributed to an increasing worldwide emphasis on developing treatments for rare and genetic diseases that currently lack effective remedies. Government funding specifically for nucleic-acid–based gene therapy accelerates progress by supplying crucial resources for research, clinical trials, and infrastructure, thereby directly driving innovation and the translation of discoveries into effective treatments. For example, in July 2023, the U.S. National Institutes of Health, a U.S.-based federal health research agency, awarded over $140 million to expedite genome editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, which marks a significant increase compared to the previous annual funding of $92 million in 2022. Therefore, the heightened financial support from governments and companies is a key driver for the growth of the nucleic acid based gene therapy market.

What Are The Major Segment Categories Within The Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

What Trends Are Influencing The Nucleic Acid Based Gene Therapy Market?

Leading companies operating in the nucleic acid-based gene therapy market are primarily focused on personalized, autologous stem-cell treatments, such as genetically modified hematopoietic stem-cell infusions, for the management of rare inherited diseases. Autologous therapies involve the removal of a patient’s own stem cells, which are then genetically corrected and re-infused to restore the missing biochemical function. For instance, in March 2024, Orchard Therapeutics, a US-based company offering pharmaceuticals, announced that Lenmeldy (atidarsagene autotemcel) had been approved by the U.S. Food and Drug Administration for use in children with metachromatic leukodystrophy (MLD). Lenmeldy utilizes the patient’s own hematopoietic stem cells, which are genetically modified to express a functional ARSA gene, thereby enabling enzyme restoration in the nervous system. This regulatory success highlights the capability of companies to commercialize intricate, autologous gene therapies despite facing high manufacturing costs.

Which Companies Form The Competitive Landscape Of The Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Access The Complete Nucleic Acid Based Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Which Region Is The Dominant Market In The Nucleic Acid Based Gene Therapy Market?

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Nucleic Acid Based Gene Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Nucleic Acid Based Gene Therapy Market During The Forecast Period?

The nucleic acid based gene therapy market size has experienced rapid expansion in recent years. This market is projected to expand from $0.88 billion in 2025 to $0.97 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. The historical growth can be credited to advancements in molecular biology research, an enhanced understanding of genetic disease mechanisms, the proliferation of clinical trials for gene therapies, increasing investment in biotechnology research, and initial regulatory approvals for nucleic acid therapies.

The nucleic acid based gene therapy market is projected to experience substantial expansion in the coming years. By 2030, it is anticipated to reach a value of $1.44 billion, growing at a compound annual growth rate (CAGR) of 10.4%. This projected growth during the forecast period can be linked to factors such as the increasing integration of CRISPR-based treatments, a heightened demand for rare disease therapies, the expansion of gene therapy manufacturing facilities, an elevated focus on personalized oncology treatments, and a rise in both public and private investment in genetic medicine. Significant trends for the forecast period include the growing adoption of RNA-based therapeutics, the increasing utilization of viral and non-viral gene delivery systems, an intensified focus on targeted gene editing technologies, the broadening of personalized genetic therapies, and a strengthened emphasis on precision medicine applications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Which Primary Drivers Are Impacting The Nucleic Acid Based Gene Therapy Market Growth?

The nucleic acid based gene therapy market is anticipated to expand due to increasing financial contributions from governments and corporations. This support includes monetary investments, grants, or subsidies from public and private institutions, aimed at advancing the research, development, and commercialization of these therapies. The heightened financial backing is attributed to a global focus on finding treatments for rare and genetic diseases that currently lack effective cures. Specifically, government funding for nucleic-acid–based gene therapy speeds up progress by supplying essential resources for research, clinical trials, and infrastructure, directly promoting innovation and the transformation into effective treatments. As an illustration, the U.S. National Institutes of Health, a U.S.-based federal health research agency, reported in July 2023 an allocation of over $140 million to accelerate genome editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders. This sum signifies a notable increase compared to the $92 million in annual funding from 2022. Ultimately, the increasing financial support from both governmental bodies and private companies is propelling the growth of the nucleic acid based gene therapy market.

What Are The Key Segment Divisions In The Nucleic Acid Based Gene Therapy Market Segment Structure?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Which Trends Are Shaping Growth In The Nucleic Acid Based Gene Therapy Market?

Major companies in the nucleic acid-based gene therapy market are increasingly focusing on personalized, autologous stem-cell therapies, such as infusions of genetically modified hematopoietic stem cells, to address rare inherited diseases. Autologous therapies involve taking a patient’s own stem cells, genetically correcting them, and then re-infusing them to restore lost biochemical function. For example, in March 2024, Orchard Therapeutics, a US-based pharmaceutical company, announced that Lenmeldy (atidarsagene autotemcel) had been approved by the U.S. Food and Drug Administration for children diagnosed with metachromatic leukodystrophy (MLD). Lenmeldy employs the patient’s own hematopoietic stem cells, which are genetically modified to express a functional ARSA gene, thereby allowing for enzyme restoration within the nervous system. This successful regulatory outcome demonstrates how firms can commercialize sophisticated, autologous gene therapies even when faced with high manufacturing expenditures.

Which Organizations Are Engaged In The Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Get The Full Nucleic Acid Based Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Which Region Dominates The Nucleic Acid Based Gene Therapy Market By Market Share?

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Nucleic Acid Based Gene Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Nucleic Acid Based Gene Therapy Market At The End Of The 2026–2030 Forecast Period?

The nucleic acid based gene therapy market size has seen rapid growth recently. It is forecast to increase from $0.88 billion in 2025 to $0.97 billion in 2026, at a compound annual growth rate (CAGR) of 10.2%. The historical period’s expansion can be linked to progress in molecular biology research, a deeper insight into genetic disease mechanisms, the broadening of clinical trials for gene therapies, rising funding in biotechnology research, and initial regulatory clearances for nucleic acid therapies.

The nucleic acid based gene therapy market is projected to experience swift expansion over the coming years. Its value is anticipated to reach $1.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. This projected growth during the forecast period stems from factors such as the increasing embrace of crispr-based treatments, a surging need for therapies targeting rare diseases, the broadening of gene therapy manufacturing capabilities, an escalating emphasis on personalized oncology treatments, and a rise in both public and private investment for genetic medicine. Key trends anticipated during the forecast period encompass a greater acceptance of rna-based therapeutics, an increasing deployment of both viral and non-viral gene delivery mechanisms, a sharpened focus on targeted gene editing technologies, the broadening of personalized genetic treatment options, and a heightened importance placed on precision medicine applications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

Which Market Drivers Are Supporting The Expansion Of The Nucleic Acid Based Gene Therapy Market?

The future expansion of the nucleic acid based gene therapy market is anticipated to be driven by increasing financial backing from both governmental bodies and corporations. This financial assistance encompasses monetary investments, grants, or subsidies offered by public or private organizations to further the research, development, and commercialization of these therapies. The increase in financial aid stems from a growing global focus on developing treatments for rare and genetic conditions that currently lack definitive cures. Government funding specifically for nucleic-acid-based gene therapy expedites advancements by providing critical resources for research, clinical trials, and foundational infrastructure, directly fostering innovation and the creation of effective treatments. For example, in July 2023, the U.S. National Institutes of Health, a federal health research agency in the U.S., reported awarding more than $140 million to expedite genome editing methods, such as CRISPR and other nucleic acid technologies, targeting rare neurological and blood disorders. This represents a substantial rise from the $92 million in annual funding provided in 2022. Consequently, the expanding financial support from governments and companies is a key factor propelling the growth of the nucleic acid based gene therapy market.

What Segment Types Make Up The Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Which Market Trends Are Creating New Opportunities In The Nucleic Acid Based Gene Therapy Market?

Prominent companies operating in the nucleic acid-based gene therapy market are directing their efforts towards personalized, autologous stem-cell therapies, including genetically modified hematopoietic stem-cell infusions, to manage rare inherited diseases. Autologous therapies describe treatments where a patient’s own stem cells are extracted, genetically rectified, and re-infused to restore the deficient biochemical function. As an illustration, in March 2024, Orchard Therapeutics, a US-based enterprise that supplies pharmaceuticals, announced the U.S. Food and Drug Administration approved Lenmeldy (atidarsagene autotemcel) for children afflicted with metachromatic leukodystrophy (MLD). Lenmeldy employs the patient’s own hematopoietic stem cells, which have been genetically altered to produce a functional ARSA gene, thereby facilitating enzyme restoration in the nervous system. This achievement in regulation demonstrates the capacity of companies to commercialize sophisticated, autologous gene therapies even with substantial manufacturing costs.

Who Are The Key Players Driving Competition In The Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Read the full nucleic acid based gene therapy market report here:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

How Is The Nucleic Acid Based Gene Therapy Market Distributed Across Key Geographic Regions?

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nucleic Acid Based Gene Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

How is the Nucleic Acid Based Gene Therapy Market size predicted to change over the forecast window of 2026–2035?

The nucleic acid based gene therapy market size has demonstrated rapid growth in recent years. It is anticipated to increase from $0.88 billion in 2025 to $0.97 billion in 2026, maintaining a compound annual growth rate (CAGR) of 10.2%. The observed growth during the historical period stems from progress in molecular biology research, a deeper understanding of genetic disease mechanisms, an increase in clinical trials for gene therapies, elevated investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.

The nucleic acid based gene therapy market is anticipated to experience substantial growth in the upcoming years. It is projected to reach $1.44 billion by 2030, displaying a compound annual growth rate (CAGR) of 10.4%. The expansion observed during this forecast period can be linked to factors such as the increasing adoption of crispr-based treatments, a rising demand for rare disease therapies, the expansion of gene therapy manufacturing facilities, a growing emphasis on personalized oncology treatments, and increased public and private funding for genetic medicine. Significant trends expected during this period include a greater adoption of rna-based therapeutics, an increasing use of viral and non-viral gene delivery systems, a heightened focus on targeted gene editing technologies, the proliferation of personalized genetic therapies, and an enhanced emphasis on precision medicine applications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

Which Drivers Are Contributing To The Expansion Of The Nucleic Acid Based Gene Therapy Market?

The anticipated expansion of the nucleic acid based gene therapy market is set to be driven by increasing financial backing from both governmental bodies and private enterprises. This financial backing encompasses monetary investments, grants, and subsidies extended by public or private entities to foster the research, development, and subsequent commercialization of these therapies. The surge in financial aid stems from a global heightened emphasis on addressing rare and genetic conditions for which effective treatments are currently lacking. Government funding directed towards nucleic-acid–based gene therapy significantly speeds up advancements by furnishing vital resources for research, clinical trials, and essential infrastructure, thereby directly propelling innovation and the translation into successful treatments. A notable illustration of this occurred in July 2023, when the U.S. National Institutes of Health, a U.S.-based federal health research agency, allocated over $140 million to accelerate genome editing approaches, including CRISPR and other nucleic acid technologies, aimed at rare neurological and blood disorders. This figure represents a considerable increase compared to the $92 million in annual funding provided in 2022. Consequently, the growing financial support from governments and companies is propelling the growth of the nucleic acid based gene therapy market.

What Segment Categories Are Covered In The Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Which Market Trends Are Opening Growth Opportunities In The Nucleic Acid Based Gene Therapy Market?

Leading companies operating within the nucleic acid-based gene therapy market are concentrating on personalized, autologous stem-cell therapies, such as genetically modified hematopoietic stem-cell infusions, to address rare inherited diseases. Autologous therapies involve extracting a patient’s own stem cells, genetically correcting them, and re-infusing them to restore missing biochemical functions. For instance, in March 2024, Orchard Therapeutics, a US-based company that offers pharmaceuticals, announced the U.S. Food and Drug Administration’s approval of Lenmeldy (atidarsagene autotemcel) for children with metachromatic leukodystrophy (MLD). Lenmeldy functions by utilizing the patient’s own hematopoietic stem cells, which have been genetically modified to express a functional ARSA gene, thus enabling enzyme restoration in the nervous system. This regulatory accomplishment emphasizes how businesses can commercialize intricate, autologous gene therapies despite facing elevated manufacturing costs.

Which Major Industry Participants Are Leading The Nucleic Acid Based Gene Therapy Market Growth?

Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Nucleic Acid Based Gene Therapy Market?

North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nucleic Acid Based Gene Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company

Genes Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Nucleic Acid Based Gene Therapy Market Expected To Become By 2029 Compared With Its 2025 Level?

The market focused on gene therapy utilizing nucleic acids has experienced significant expansion lately; its valuation is projected to advance from $0.81 billion in 2024 to reach $0.88 billion by the subsequent year, exhibiting a compound annual growth rate of 8.4%. This upward trajectory during the past period stems from several key factors including an increasing comprehension of human genetic makeup, a rising need for individualized medical treatments, an augmenting portfolio of forthcoming gene therapy solutions, greater governmental backing for gene therapy methods, and ongoing work in treating genetic ailments and various cancers.

Anticipation surrounds the nucleic acid based gene therapy sector, projecting substantial expansion in the impending years, with its market valuation projected to ascend to $1.3 billion by 2029, reflecting a consistent annual growth trajectory of 10.3%. This upward momentum throughout the predicted timeframe stems from several key factors, notably the broadening range of conditions being targeted, augmented financial support, heightened patient awareness and advocacy efforts, surging capital allocation toward gene therapy research and development endeavors, the widening applicability of gene therapy modalities, and a focus on addressing rare medical conditions. Key developments shaping the outlook for this period encompass innovations in ex vivo gene editing techniques, progress made in in vivo gene modification methods, the adoption of combination treatment approaches, the refinement of targeted delivery mechanisms, gene editing specifically applied to heretofore untreatable rare diseases, and the increased utilization of non-viral vectors.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Nucleic Acid Based Gene Therapy Industry?

Anticipated growth in demand for nucleic acid-based gene therapy is forecasted to be propelled by increased financial backing from both governmental bodies and private enterprises. These nucleic acid therapeutics function as mimics of the natural acids or proteins that govern genetic expression. Conventional treatment modalities unfortunately lack curative options for conditions like cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The foundation of these therapeutic categories rests upon genetic profiling along with pinpointing molecular targets. Given that nucleic acid medications address the underlying genetic causes of illnesses, offering a permanent resolution, they possess significant prospective value for managing these ailments. Furthermore, escalating financial commitments from governmental agencies and market participants involved in gene therapy are set to boost the overall demand for the nucleic acid-based gene therapy sector; as an illustration, in August 2022, the National Institute of Health (NIH) committed to an annual investment of $34 million spanning the next five years aimed at advancing HIV treatment investigations, thereby indicating that state sponsorship for gene therapies will fuel expansion within the nucleic acid-based gene therapy market.

What Are The Emerging Segments Gaining Attention In The Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapymarket covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Which Industry Leaders Are Driving Innovation Across The Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market include Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

How Does The Nucleic Acid Based Gene Therapy Market Perform Across Key Geographic Regions?

North America was the largest region in the nucleic acid-based gene therapy market in 2024. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Request A Customized Version Of The Nucleic Acid Based Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2025, By The Business Research Company

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Next Generation Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Nucleic Acid Based Gene Therapy Market Expected To Become By 2029 Compared With Its 2025 Level?

The market focused on gene therapy utilizing nucleic acids has experienced significant expansion lately; its valuation is projected to advance from $0.81 billion in 2024 to reach $0.88 billion by the subsequent year, exhibiting a compound annual growth rate of 8.4%. This upward trajectory during the past period stems from several key factors including an increasing comprehension of human genetic makeup, a rising need for individualized medical treatments, an augmenting portfolio of forthcoming gene therapy solutions, greater governmental backing for gene therapy methods, and ongoing work in treating genetic ailments and various cancers.

Anticipation surrounds the nucleic acid based gene therapy sector, projecting substantial expansion in the impending years, with its market valuation projected to ascend to $1.3 billion by 2029, reflecting a consistent annual growth trajectory of 10.3%. This upward momentum throughout the predicted timeframe stems from several key factors, notably the broadening range of conditions being targeted, augmented financial support, heightened patient awareness and advocacy efforts, surging capital allocation toward gene therapy research and development endeavors, the widening applicability of gene therapy modalities, and a focus on addressing rare medical conditions. Key developments shaping the outlook for this period encompass innovations in ex vivo gene editing techniques, progress made in in vivo gene modification methods, the adoption of combination treatment approaches, the refinement of targeted delivery mechanisms, gene editing specifically applied to heretofore untreatable rare diseases, and the increased utilization of non-viral vectors.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Nucleic Acid Based Gene Therapy Industry?

Anticipated growth in demand for nucleic acid-based gene therapy is forecasted to be propelled by increased financial backing from both governmental bodies and private enterprises. These nucleic acid therapeutics function as mimics of the natural acids or proteins that govern genetic expression. Conventional treatment modalities unfortunately lack curative options for conditions like cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The foundation of these therapeutic categories rests upon genetic profiling along with pinpointing molecular targets. Given that nucleic acid medications address the underlying genetic causes of illnesses, offering a permanent resolution, they possess significant prospective value for managing these ailments. Furthermore, escalating financial commitments from governmental agencies and market participants involved in gene therapy are set to boost the overall demand for the nucleic acid-based gene therapy sector; as an illustration, in August 2022, the National Institute of Health (NIH) committed to an annual investment of $34 million spanning the next five years aimed at advancing HIV treatment investigations, thereby indicating that state sponsorship for gene therapies will fuel expansion within the nucleic acid-based gene therapy market.

What Are The Emerging Segments Gaining Attention In The Nucleic Acid Based Gene Therapy Market?

The nucleic acid based gene therapymarket covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Which Industry Leaders Are Driving Innovation Across The Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market include Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

How Does The Nucleic Acid Based Gene Therapy Market Perform Across Key Geographic Regions?

North America was the largest region in the nucleic acid-based gene therapy market in 2024. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Request A Customized Version Of The Nucleic Acid Based Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2025, By The Business Research Company

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Next Generation Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Nucleic Acid Based Gene Therapy Market Size from 2025 to 2034?

In recent times, the market size of nucleic acid based gene therapy has seen robust growth. The market, which was worth $0.81 billion in 2024, is estimated to increase to $0.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the historical period include better comprehension of human genetics, a rising demand for personalized medicine, expansion in the product pipeline of gene therapy, increased government backing for gene therapy, along with genetic disorders, and cancer therapy.

The market size of nucleic acid-based gene therapy is projected to witness substantial expansion in the upcoming years. It is anticipated to hit a benchmark of $1.3 billion in 2029 with a 10.3% compound annual growth rate (CAGR). The growth within this period can be attributed to increasing indications, enhanced funding, rising awareness and patient advocacy. In addition, there is an increase in investment for the research and development of gene therapy and broadened areas of gene therapy applications for rare diseases. The key trends during this forecast period encompass ex vivo gene editing, progress in in vivo gene editing, combination therapies, precision delivery systems, and gene editing aimed at rare diseases, along with non-viral vectors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Nucleic Acid Based Gene Therapy Market?

The increase in financial backing from both government and corporate entities is predicted to escalate the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics, considered analogs of organic acids or proteins crucial for genetic manifestation, form part of a new wave of treatment. Traditional methods have been unable to discover cures for conditions like cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The success of these innovative drugs depends significantly on genetic profiling and molecular target identification. Nucleic acid medicines, which pinpoint the genetic origin of diseases, have the potential to provide permanent solutions. The escalating financial aid from governments and businesses in the gene therapy market is anticipated to boost the demand for nucleic acid-based gene therapies. For example, the National Institute of Health (NIH) stated in August 2022 that it plans to invest $34 million annually for the next five years into HIV treatment research. This government support is expected to stimulate the growth of the nucleic acid based gene therapy market.

Which Key Market Segments Comprise the Nucleic Acid Based Gene Therapy Market and Drive Its Revenue Growth?

The nucleic acid based gene therapymarket covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Which Areas Are Leading Regions in the Nucleic Acid Based Gene Therapy Market Expansion Across the Globe?

North America was the largest region in the nucleic acid-based gene therapy market in 2024. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

View the full report here:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

How Is the Nucleic Acid Based Gene Therapy Market Conceptually Defined?

Nucleic acid-based gene therapy is a medical treatment approach that uses nucleic acids (such as DNA or RNA) to modify or manipulate genes within a patient’s cells to treat or prevent diseases. This therapy aims to address the root cause of a disease at the genetic level by directly intervening in the genetic material that leads to the malfunctioning of cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2820

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Nucleic Acid Based Gene Therapy Market Size from 2025 to 2034?

In recent times, the market size of nucleic acid based gene therapy has seen robust growth. The market, which was worth $0.81 billion in 2024, is estimated to increase to $0.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the historical period include better comprehension of human genetics, a rising demand for personalized medicine, expansion in the product pipeline of gene therapy, increased government backing for gene therapy, along with genetic disorders, and cancer therapy.

The market size of nucleic acid-based gene therapy is projected to witness substantial expansion in the upcoming years. It is anticipated to hit a benchmark of $1.3 billion in 2029 with a 10.3% compound annual growth rate (CAGR). The growth within this period can be attributed to increasing indications, enhanced funding, rising awareness and patient advocacy. In addition, there is an increase in investment for the research and development of gene therapy and broadened areas of gene therapy applications for rare diseases. The key trends during this forecast period encompass ex vivo gene editing, progress in in vivo gene editing, combination therapies, precision delivery systems, and gene editing aimed at rare diseases, along with non-viral vectors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Nucleic Acid Based Gene Therapy Market?

The increase in financial backing from both government and corporate entities is predicted to escalate the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics, considered analogs of organic acids or proteins crucial for genetic manifestation, form part of a new wave of treatment. Traditional methods have been unable to discover cures for conditions like cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The success of these innovative drugs depends significantly on genetic profiling and molecular target identification. Nucleic acid medicines, which pinpoint the genetic origin of diseases, have the potential to provide permanent solutions. The escalating financial aid from governments and businesses in the gene therapy market is anticipated to boost the demand for nucleic acid-based gene therapies. For example, the National Institute of Health (NIH) stated in August 2022 that it plans to invest $34 million annually for the next five years into HIV treatment research. This government support is expected to stimulate the growth of the nucleic acid based gene therapy market.

Which Key Market Segments Comprise the Nucleic Acid Based Gene Therapy Market and Drive Its Revenue Growth?

The nucleic acid based gene therapymarket covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Which Areas Are Leading Regions in the Nucleic Acid Based Gene Therapy Market Expansion Across the Globe?

North America was the largest region in the nucleic acid-based gene therapy market in 2024. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

View the full report here:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

How Is the Nucleic Acid Based Gene Therapy Market Conceptually Defined?

Nucleic acid-based gene therapy is a medical treatment approach that uses nucleic acids (such as DNA or RNA) to modify or manipulate genes within a patient’s cells to treat or prevent diseases. This therapy aims to address the root cause of a disease at the genetic level by directly intervening in the genetic material that leads to the malfunctioning of cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2820

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model